MRI for radiotherapy treatment planning of stage III NSCLC: an MRI optimization study in healthy volunteers and patients

Completed

Conditions: 10038666
10029107
lung cancer
non-small cell lung cancer

Registration Number: NL-OMON44655

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

Healthy volunteers
- *18 years
- written informed consent;Patients:
- patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0) referred to the department of Radiation Oncology
- * 18 years
- written informed consent
- recent (* 3 months) GFR value available

Exclusion Criteria

Healthy volunteers:
- volunteers who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht;Patients:
- patients who meet exclusion criteria for MRI following the protocol of the department of Radiology of the UMC Utrecht
- patients for whom lying still in a supine position for 45 minutes is physically too strenuous (e.g. due to orthopnea)
- Glomerular Filtration Rate (GFR) of <30 mL/min/1.73m2 (UMCU protocol *MRI Contra-indicaties*, Version 3 January 2013)
- patients with nephrogenic systemic fibrosis, nephrogenic fibrosing dermopathy or severe renal insufficiency (UMCU protocol *MRI Contra-indicaties*, Version 3 January 2013)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>* Healthy volunteers:<br /><br>Quality of the scans will be assessed by rating the motion artifacts and<br /><br>visibility of the lung and mediastinal parenchyma.<br /><br><br /><br>* Patients with stage III NSCLC:<br /><br>Optimization of lung MRI for radiotherapy purposes (i.e. tumor delineation and<br /><br>motion characterization) defined by the quality of the images. Quality will be<br /><br>assessed by rating of the scans regarding the visibility of the primary tumor,<br /><br>lymph nodes and mediastinal parenchyma.</p><br>

Secondary Outcome Measures